Document is current
Any future updates will be listed below
-
Authors
Coukos, George https://orcid.org/0000-0001-8813-7367
Donia, Marco https://orcid.org/0000-0003-4966-9752
Gastman, Brian R
Goff, Stephanie L https://orcid.org/0000-0003-3317-9804
Gros, Alena
Harari, Alexandre
Hernandez, Sophia
Ito, Fumito https://orcid.org/0000-0002-6866-671X
Maker, Ajay V
Mullinax, John E https://orcid.org/0000-0002-9596-6785
Murthy, Pranav
Pai, Sara I https://orcid.org/0000-0002-6341-9971
Prabhakaran, Sangeetha
Restifo, Nicholas P
Silver, Natalie L
Marincola Smith, Paula
Turcotte, Simon
Wagner, Patrick L
Yang, James C https://orcid.org/0000-0001-8935-5008
Lotze, Michael T https://orcid.org/0000-0003-3988-5419
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05468307 at ClinicalTrials.govnct05902520 at ClinicalTrials.govDocuments that mention this clinical trial
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
A phase I single-arm, open-label trial of engineering tumor-infiltrating lymphocytes with membrane-bound IL-7 for recurrent ovarian cancer.
https://doi.org/10.1200/jco.2024.42.16_suppl.5552
nct05902520 at ClinicalTrials.govDocuments that mention this clinical trial
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
592 Phase I study: CD39 <sup>+</sup> CD103 <sup>+</sup> CD8 <sup>+</sup> selected TIL therapy (AGX-148) demonstrates clinical activity in patients with metastatic solid tumors
https://doi.org/10.1136/jitc-2025-sitc2025.0592
nct03645928 at ClinicalTrials.govDocuments that mention this clinical trial
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
592 Phase I study: CD39 <sup>+</sup> CD103 <sup>+</sup> CD8 <sup>+</sup> selected TIL therapy (AGX-148) demonstrates clinical activity in patients with metastatic solid tumors
https://doi.org/10.1136/jitc-2025-sitc2025.0592
nct02858310 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2021-sitc2021.458
492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers
https://doi.org/10.1136/jitc-2021-sitc2021.492
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
1488 A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results
https://doi.org/10.1136/jitc-2024-sitc2024.1488
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.
https://doi.org/10.1200/jco.2024.42.16_suppl.9505
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007218
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2020-000668
nct06236425 at ClinicalTrials.govDocuments that mention this clinical trial
38 Liquid biopsy detects treatment resistance to T cell receptor (TCR)-T cell therapy
https://doi.org/10.1136/jitc-2025-sitc2025.0038
Advances in immunotherapy in cervical cancer
https://doi.org/10.1136/ijgc-2022-003758
Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy
https://doi.org/10.1136/jitc-2022-004790
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
https://doi.org/10.1136/jitc-2020-002128
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
nct04072263 at ClinicalTrials.govDocuments that mention this clinical trial
A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC).
https://doi.org/10.1200/jco.2024.42.16_suppl.tps6115
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
nct05468307 at ClinicalTrials.govDocuments that mention this clinical trial
356 Personalized immunotherapy by adoptive T cell transfer during chemotherapy with or without interferon-alpha in patients with recurrent platinum-sensitive epithelial ovarian cancer
https://doi.org/10.1136/jitc-2021-sitc2021.356
PO008/#393 Timed adoptive T-cell therapy during chemotherapy in platinum sensitive recurrent epithelial ovarian cancer, the ovacure phase I/II trial
https://doi.org/10.1136/ijgc-2023-igcs.8
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer
https://doi.org/10.1136/jitc-2023-007697
nct04052334 at ClinicalTrials.govDocuments that mention this clinical trial
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
A phase I single-arm, open-label trial of engineering tumor-infiltrating lymphocytes with membrane-bound IL-7 for recurrent ovarian cancer.
https://doi.org/10.1200/jco.2024.42.16_suppl.5552
nct03725605 at ClinicalTrials.govDocuments that mention this clinical trial
Cell therapy in sarcoma: current landscape and future directions
https://doi.org/10.1136/jitc-2025-013396
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
nct06566092 at ClinicalTrials.govDocuments that mention this clinical trial
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
nct06474676 at ClinicalTrials.govDocuments that mention this clinical trial
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
nct03935893 at ClinicalTrials.govDocuments that mention this clinical trial
Cell therapy in sarcoma: current landscape and future directions
https://doi.org/10.1136/jitc-2025-013396
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
nct05607095 at ClinicalTrials.govDocuments that mention this clinical trial
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
https://doi.org/10.1136/jitc-2020-001065
Cell therapy in sarcoma: current landscape and future directions
https://doi.org/10.1136/jitc-2025-013396
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
nct06566092 at ClinicalTrials.govDocuments that mention this clinical trial
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
nct06236425 at ClinicalTrials.govDocuments that mention this clinical trial
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
nct06783270 at ClinicalTrials.govDocuments that mention this clinical trial
A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC).
https://doi.org/10.1200/jco.2024.42.16_suppl.tps6115
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
Documents that mention this clinical trial
Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges
https://doi.org/10.1136/bmjonc-2024-000566
601 Assessment of CRISPR PD-1 edited tumor-infiltrating lymphocytes in infusion products for adoptive cell therapy in metastatic melanoma
https://doi.org/10.1136/jitc-2025-sitc2025.0601
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
- License Information
